Comparative Pharmacology
Head-to-head clinical analysis: KOSELUGO versus MEKINIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOSELUGO versus MEKINIST.
KOSELUGO vs MEKINIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of MEK1 and MEK2, downstream kinases in the RAS/RAF/MEK/ERK signaling pathway. Inhibits cell proliferation and induces apoptosis in tumor cells with activating mutations in BRAF or RAS.
Reversible, selective inhibitor of MEK1 and MEK2, which are downstream kinases in the RAS/RAF/MEK/ERK signaling pathway. Inhibition prevents phosphorylation and activation of ERK, thereby reducing cell proliferation in BRAF V600 mutant tumors.
600 mg orally twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
2 mg orally once daily, at least 1 hour before or 2 hours after a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 23-25 hours, supporting once-daily dosing with steady-state achieved within 5 days.
Terminal half-life of 3.9 days (93.6 hours) in patients; supports once-daily dosing and steady-state achieved in ~19 days
Primarily excreted via feces (94%) with minimal renal excretion (<1% unchanged in urine). Biliary excretion accounts for a minor pathway.
Fecal (80% as unchanged drug and metabolites), renal (<1% unchanged)
Category C
Category C
MEK Inhibitor
MEK Inhibitor